Sinopharm Dongfeng General Hospital (Hubei Clinical Research Center of Hypertension), Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China.
Children's Medical Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Front Endocrinol (Lausanne). 2024 Sep 20;15:1465881. doi: 10.3389/fendo.2024.1465881. eCollection 2024.
Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids. It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases. In this study, the potential effects of GLP-1RAs on the occurrence and development of tumors were reviewed to provide new ideas for the prevention and treatment of tumors in patients.
胰高血糖素样肽-1 受体激动剂（GLP-1RA）是一种新型的降血糖药物，可用于治疗 2 型糖尿病，具有降低血糖、改善炎症、减轻体重和降低血脂等众所周知的作用。此外，它还可以影响细胞的增殖和存活，并对某些肿瘤疾病的预后有一定影响。本研究旨在探讨 GLP-1RAs 对肿瘤发生发展的潜在影响，为患者肿瘤的预防和治疗提供新思路。
